Health care stocks declined Friday afternoon with the NYSE Health Care Index down 0.4% and the Health Care Select Sector SPDR Fund (XLV) falling 0.2%.
The iShares Biotechnology ETF (IBB) decreased 0.3%.
In corporate news, Medtronic (MDT) shares fell 0.7%. JPMorgan cut its price target on the stock to $87 from $95.
Bicara Therapeutics (BCAX) shares tumbled 45%, a day after the company said its phase 1/1b trial of ficerafusp alfa with pembrolizumab in people with head and neck squamous cell carcinoma hasn't yet reached median overall survival and median duration of response based on interim results.
Imunon (IMNN) shares more than doubled. The company received positive data showing an improvement in overall and progression-free survival from a phase 2 trial of IMNN-001, an investigational therapy to treat ovarian cancer.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。